Research Article

Related GMR Articles

10/31/2014
Chemotherapy; Excision repair cross-complementation group 1; Non-small cell lung cancer; Single nucleotide polymorphism; Survival time

We conducted a cohort study to investigate the role of 3 single-nucleotide polymorphisms of the excision repair cross-complementation group 1 (ERCC1) gene on the response to chemotherapy and clinical outcomes of non-small cell lung cancer (NSCLC). A total of 163 patients with newly diagnosed and histopathologically confirmed primary NSCLC were examined in our study and were ... more

H. Gao; R.C. Ge; H.Y. Liu; Y. Wang; S. Yan
05/16/2014
Chemotherapy; Gene polymorphism; Lung cancer; Meta-analysis; Platinum; XRCC1

X-ray repair cross complementing group 1(XRCC1) polymorphisms have been implicated in interindividual variability of efficacy of platinum chemotherapy for treating non-small cell lung cancer (NSCLC); however, results of different studies have been inconsistent. We conducted a meta-analysis to investigate the association between polymorphisms in the XRCC1 gene and ... more

L. Li; C. Wan; F.Q. Wen
03/06/2014
Chemotherapy; Gastric cancer; Meta-analysis; Polymorphism; XRCC1

It is still controversial whether X-ray repair cross-complementing group (XRCC1) gene polymorphisms (Arg194Trp and Arg399Gln) are associated with the clinical outcome of platinum-based chemotherapy in gastric cancer patients based on published studies. Meta-analysis was performed to provide a systematic review of the findings. Eligible articles from the PubMed, SinoMed, and CNKI ... more

J. Xu; J. Ma; H.T. Zong; S.Y. Wang; J.W. Zhou
02/19/2008
Breast cancer; Chemotherapy; P-glycoprotein; Polymorphism

Primary chemotherapy is a useful strategy for the treatment of locally advanced breast cancer and therefore allows in vivo evaluation of the action of cytotoxic drugs and the possibility of accomplishing conservative breast surgeries, as well as the early treatment of metastasis. Mechanisms of resistance to the drugs include the action of protein associated with the efflux of drugs from ... more

F.F.O. Rodrigues; R.E. Santos; M.B. Melo; M.A.L.G. Silva; A.L. Oliveira; R.L. Rozenowicz; L.B. Ulson; T. Aoki
04/30/2015
Chemotherapy; Clinical outcome; Osteosarcoma; Vascular endothelial growth factors

We investigated the association between vascular endothelial growth factor (VEGF) gene +1612G/A, -634C/G, and +936G/C and the clinical outcome of osteosarcoma. Genomic DNA was isolated from blood samples, and 3 VEGF gene polymorphisms (+1612G/A, -634C/G, and +936G/C) were analyzed using polymerase chain reaction-restriction fragment length polymorphism. Of the 194 patients, 82 patients ( ... more

X.D. Li; D.D. Yu; J.R. Lu; C. Wu; W.X. Jin
04/13/2015
Cancer stem cells; Chemotherapy; Medulloblastoma; Multidrug resistance; Side population

Brain cancer stem cells are a subset of tumor cells present in several types of brain tumor that evade treatment regimens and are responsible for tumor recurrence. Recent reports on several tumors have suggested that Hoechst 33342 dye exclusion is a powerful technique for isolating cancer stem cell-like side population (SP) cells. In the present study, we attempted to isolate the SP cells ... more

J. Liu; N. Chi; J.Y. Zhang; W. Zhu; Y.S. Bian; H.G. Chen
04/17/2014
ERCC5; Non-small cell lung cancer; SNPs; XRCC1

We aimed to assess the role of polymorphisms of the XRCC1 Arg194Trp, XRCC1 Arg399Gln, ERCC5 His1104Asp, and ERCC5 His46His genes on clinical outcomes of advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy regimens. A total of 378 NSCLC patients were asked to participate within 1 month after diagnosis between January 2005 and January 2006, and they ... more

D. Liu; J. Wu; G.Y. Shi; H.F. Zhou; Y. Yu
05/16/2014
Clinical outcome; Hepatocellular carcinoma; Polymorphism; susceptibility; XPD; XRCC1

We explored the association between 4 XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms with the development and prognosis of hepatocellular carcinoma (HCC). A total of 218 cases with HCC and 277 healthy controls were included in the study. Genotyping of the XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms was ... more

J.S. Wu; Y.P. Chen; L.C. Wang; Y.J. Yang; C.W. Deng; B.X. Hou; Z.L. He; J.X. Chen
01/21/2014
Chemotherapy; Local infusion; Pleural tumor; Surgical treatment; Tumors

The aim of this study was to evaluate effective treatment methods of malignant pleural mesothelioma (MPM). Twenty-three patients with MPM were cured by pleural infusion chemotherapy after surgery. Median survival time and the 1-, 2-, and 3-year survival rates were analyzed on the basis of follow-up. Median survival time of all patients was 15 months (range: 3 to 89 months); the 1-, 2-, ... more

J. Zhang; Q. Zhang; W. Zhao; J. Duan; T. Huang
03/30/2015
Chemotherapy; High-risk factors; Non-Hodgkin lymphoma

The goal of this study was to investigate damaged liver function after chemotherapy in hepatitis B virus (HBV) carriers with non-Hodgkin lymphoma (NHL) and to evaluate risk factors associated with a high risk of damaged liver function. Clinical histories of 134 HBV carriers with NHL who were treated with chemotherapy were obtained and analyzed for the occurrence of damaged liver function ... more

X. Li; X.W. Fan; W. Liu; L. Guo; Y. Li; X. Hu; X. Liang; X.P. Ma; S.E. Yang

Pages